EGI
BSTC

EAM Global Investors’s BioSpecifics Technologies Corp. BSTC Stock Holding History

EAM Global Investors’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-22,789
Closed -$1.42M – 166
2019
Q1 		$1.42M Hold
22,789
– – 0.63% 78
2018
Q4 		$1.38M Buy
22,789
+2,147
+10% +$128K 0.76% 63
2018
Q3 		$1.21M Buy
+20,642
New +$1.05M 0.49% 114

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Global Investors's BSTC Position: Q2 2019 in Review

EAM Global Investors sold out of BioSpecifics Technologies Corp. (BSTC) in Q2 2019, closing a stake of 22,789 shares — an estimated $1.42M sold.

EAM Global Investors first reported a position in BSTC in Q3 2018 and held it in 3 quarters. The position peaked at $1.42M in Q1 2019. 114 funds tracked by Wall St. Rank hold BSTC as of Q2 2019.

  • EAM Global Investors reported no remaining BioSpecifics Technologies Corp. position as of Q2 2019 after selling out during the quarter.
  • EAM Global Investors sold 22,789 BioSpecifics Technologies Corp. shares in Q2 2019, an estimated $1.42M.
  • EAM Global Investors first reported a position in BioSpecifics Technologies Corp. in Q3 2018 and held it in 3 quarters.
  • EAM Global Investors's BioSpecifics Technologies Corp. position peaked at $1.42M in Q1 2019.
  • 114 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2019.

Based on EAM Global Investors's 13F filing for Q2 2019, filed 14 Aug 2019.